Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients

Functional toll-like receptors (TLRs) could modulate anti-tumor effects by activating inflammatory cytokines and the cytotoxic T-cells response. However, excessive TLR expression could promote tumor progression, since TLR-induced inflammation might stimulate cancer cells expansion into the microenvironment. Myd88 is involved in activation NF-κB through TLRs downstream signaling, hence in the current study we provided, for the first time, a complex characterization of expression of TLR2, TLR4, TLR7, TLR9, and MYD88 as well as their splicing forms in two distinct compartments of the microenvironment of chronic lymphocytic leukemia (CLL): peripheral blood and bone marrow. We found correlations between MYD88 and TLRs expressions in both compartments, indicating their relevant cooperation in CLL. The MYD88 expression was higher in CLL patients compared to healthy volunteers (HVs) (0.1780 vs. 0.128, p < 0.0001). The TLRs expression was aberrant in CLL compared to HVs. Analysis of survival curves revealed a shorter time to first treatment in the group of patients with low level of TLR4(3) expression compared to high level of TLR4(3) expression in bone marrow (13 months vs. 48 months, p = 0.0207). We suggest that TLRs expression is differentially regulated in CLL but is similarly shared between two distinct compartments of the microenvironment.

[1]  Nan Li,et al.  Corrigendum to "TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance" [Mol. Immunol. 44 (2007) 2850-2859]. , 2020, Molecular immunology.

[2]  M. Lunning,et al.  Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL , 2019, Current Hematologic Malignancy Reports.

[3]  K. Giannopoulos,et al.  Deregulation of the immune system in patients with chronic lymphocytic leukemia , 2019, Postępy Higieny i Medycyny Doświadczalnej.

[4]  J. D. Díaz Arias,et al.  Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns , 2019, Front. Oncol..

[5]  Huihao Zhang,et al.  TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells , 2018, Molecular medicine reports.

[6]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[7]  Jae Young Kim,et al.  Identification and Characterization of a Splicing Variant in the 5′ UTR of the Human TLR5 Gene , 2017, BioMed research international.

[8]  Jian-yong Li,et al.  MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene , 2017, Blood Cancer Journal.

[9]  K. Kuliczkowski,et al.  The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia , 2016, Archivum Immunologiae et Therapiae Experimentalis.

[10]  A. Karczmarczyk,et al.  Specific cytotoxic T‐cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells , 2016, British journal of haematology.

[11]  P. Moss,et al.  Perturbation of the normal immune system in patients with CLL. , 2015, Blood.

[12]  A. Karczmarczyk,et al.  Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia , 2015, Acta Haematologica.

[13]  Huihao Zhang,et al.  Significance of TLR4/MyD88 expression in breast cancer. , 2015, International journal of clinical and experimental pathology.

[14]  K. Horikawa,et al.  Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation , 2014, Front. Immunol..

[15]  Dong Chang Lee,et al.  Toll like Receptor 3 & 4 Responses of Human Turbinate Derived Mesenchymal Stem Cells: Stimulation by Double Stranded RNA and Lipopolysaccharide , 2014, PloS one.

[16]  K. Stamatopoulos,et al.  Heterogeneous Functional Effects of Concomitant B Cell Receptor and TLR Stimulation in Chronic Lymphocytic Leukemia with Mutated versus Unmutated Ig Genes , 2014, The Journal of Immunology.

[17]  D. Klinman,et al.  Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors , 2014, Journal of Immunotherapy for Cancer.

[18]  D. Consonni,et al.  Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression , 2014, Leukemia & lymphoma.

[19]  N. Rezaei,et al.  Toll-like receptors in lymphoid malignancies: double-edged sword. , 2014, Critical reviews in oncology/hematology.

[20]  F. caligaris-Cappio,et al.  How the microenvironment wires the natural history of chronic lymphocytic leukemia. , 2014, Seminars in cancer biology.

[21]  X. Sheng,et al.  TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro , 2013, Oncology letters.

[22]  M. Zając,et al.  Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients. , 2013, Human immunology.

[23]  P. Pilarski,et al.  A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets , 2013, Clinical Cancer Research.

[24]  G. Trinchieri,et al.  MyD88 and its divergent toll in carcinogenesis. , 2013, Trends in immunology.

[25]  A. Dmoszyńska,et al.  Aberrant TIRAP and MyD88 expression in B-cell chronic lymphocytic leukemia. , 2013, Blood cells, molecules & diseases.

[26]  Jing Yang,et al.  Toll‐like receptor‐4 signaling in mantle cell lymphoma , 2013, Cancer.

[27]  A. Dmoszyńska,et al.  TLR2 may influence the behavior of the malignant clone in B-CLL. , 2012, Blood cells, molecules & diseases.

[28]  L. Llorente,et al.  Immunological aspects in chronic lymphocytic leukemia (CLL) development , 2012, Annals of Hematology.

[29]  M. I. Crespo,et al.  IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. , 2012, Cancer research.

[30]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[31]  Stavroula Ntoufa,et al.  Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients , 2011, Haematologica.

[32]  N. Chiorazzi,et al.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. , 2010, Blood.

[33]  R. Spíšek,et al.  Toll‐like receptors on B‐CLL cells: expression and functional consequences of their stimulation , 2010, International journal of cancer.

[34]  M. Vega,et al.  The significance of toll-like receptors in human diseases. , 2009, Allergologia et immunopathologia.

[35]  T. Whiteside,et al.  TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer , 2009, Oncogene.

[36]  Paolo Ghia,et al.  Expression and function of toll like receptors in chronic lymphocytic leukaemia cells , 2009, British journal of haematology.

[37]  R. Rosenquist,et al.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. , 2008, Blood.

[38]  P. Feugier,et al.  Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells , 2007, Haematologica.

[39]  Jun Kawai,et al.  Alternate transcription of the Toll-like receptor signaling cascade , 2006, Genome Biology.

[40]  A. Lanzavecchia,et al.  A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. , 2003, Blood.

[41]  G Leone,et al.  The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease , 2007, Leukemia.